Understanding resistance mechanisms in acute myeloid leukemia treatments
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia
This study is looking at how acute myeloid leukemia (AML) can become resistant to new treatments, especially certain medications, by examining samples from over 2,500 patients to find clues that help explain why some people respond well while others don’t, with the hope of making treatments better for everyone.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11113819 on NIH RePORTER |
What this research studies
This research investigates how acute myeloid leukemia (AML) develops resistance to new treatments, specifically focusing on the FLT3 and BCL2 inhibitors. By analyzing over 2,500 patient samples, the team aims to identify biomarkers that indicate how patients respond to these therapies and why some experience relapse. The approach combines various advanced techniques, including proteomics and genomics, to gain insights into the disease's complexity. Ultimately, the goal is to improve treatment strategies by preventing resistance and enhancing patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are undergoing treatment with FLT3 or BCL2 inhibitors.
Not a fit: Patients with other types of leukemia or those not receiving FLT3 or BCL2 inhibitor treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment combinations that prevent drug resistance in AML patients.
How similar studies have performed: Other research has shown promise in understanding resistance mechanisms in leukemia treatments, suggesting that this approach could yield valuable insights.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Tyner, Jeffrey Wallace — Oregon Health & Science University
- Study coordinator: Tyner, Jeffrey Wallace
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.